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Background: Recent studies have shown that the recently identified organism Candida dubliniensis is less
pathogenic than the more common Candida albicans. Due to its rare nature, C. dubliniensis has been previously
reported as the causative organism in endophthalmitis in only three cases. We undertook a multicenter,
retrospective, consecutive case series to describe the clinical features and outcomes of patients with culture-proven
C. dubliniensis endophthalmitis. Medical records were reviewed for all patients with C. dubliniensis endophthalmitis
on vitreous/aqueous cultures from June 1998 to June 2013 from all public hospitals throughout Queensland,
Australia.
Results: Six eyes from five patients were identified - four males and one female aged from 21 to 55 years (mean
37 years). Four patients were intravenous drug users and four patients had hepatitis C. All five patients were treated
with systemic antifungal therapy and intravitreal antifungal injections, and all required vitrectomy. Two eyes
developed retinal detachment over the course of the endophthalmitis. Five eyes had visual outcomes of 20/60 or
better, and one eye had a poor outcome with final visual acuity of hand movements only. There was no associated
mortality, and no infected eyes required enucleation or evisceration.
Conclusions: C. dubliniensis endophthalmitis is a rare condition which occurs mainly in intravenous drug users and
can occur in both HIV-positive and HIV-negative patients. Unlike C. albicans endophthalmitis, C. dubliniensis
endophthalmitis has reasonable visual outcomes and does not appear to be associated with high mortality.
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Endogenous fungal endophthalmitis is a rare, poten-
tially blinding complication of systemic fungal infection.
Overall, the commensal yeast Candida albicans is the
most common fungal isolate in patients with endogen-
ous fungal endophthalmitis, although other Candida
strains have been implicated as causative organisms in-
cluding Candida tropicalis, Candida parapsilosis, Candida
glabrata, Candida guilliermondii, Candida krusei, and
more recently Candida dubliniensis [1]. C. dubliniensis was
first identified in 1995 in Ireland as an oral commensal
isolated from HIV-infected individuals and has since been
isolated in a variety of other candidal infections [2]. Al-
though C. dubliniensis was initially identified as an ‘atypical’
form of the more common C. albicans, subsequent pheno-
typic and genotypic studies have identified it as a separate* Correspondence: thomas.moloney@health.qld.gov.au
Department of Ophthalmology, The Royal Brisbane and Women's Hospital,
Herston, Brisbane, Queensland 4006, Australia
© 2013 Moloney and Park; licensee Springer. T
Commons Attribution License (http://creativeco
reproduction in any medium, provided the origstrain [2]. Further studies have shown that C. dubliniensis
and C. albicans differ not only phenotypically but also in
terms of epidemiology, virulence characteristics, and the
ability of C. dubliniensis to develop fluconazole resistance
[3]. Due to these variations, it is important to differentiate
these strains in clinical situations like Candida endoph-
thalmitis due to potential differences in presentation,
treatment, and clinical outcomes. To our knowledge, there
have been only three previously reported cases of endoph-
thalmitis caused by C. dubliniensis since the discovery of
the organism [4-6]. We report and discuss the significance
of five new cases of C. dubliniensis endophthalmitis identi-
fied over 15 years in public hospitals in Queensland,
Australia.
Methods
Queensland public hospital pathology records were
reviewed for all patients with endophthalmitis and
vitreous/aqueous samples that cultured C. dubliniensishis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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Five patients were identified over this period. The
medical records of these patients were then retrospect-
ively reviewed for demographic data, background medical
history, presenting signs and symptoms, diagnostic testing,
microbiology results, treatment received, visual outcome,
and mortality. This review was conducted in accordance
with guidelines set forth by the Declaration of Helsinki
and was exempt from institutional review board approval.
Results
Age, sex, and predisposing factors
Six eyes from four males and one female aged from 21
to 55 years (mean 37 years) were identified for our series
(Tables 1 and 2). All patients had endogenous endoph-
thalmitis, but only two patients had other symptoms of
systemic illness with the other three patients having iso-
lated endophthalmitis only. Four patients had a back-
ground of intravenous drug use (80%), four patients had
hepatitis C (80%), one patient had associated liver cir-
rhosis (20%), and one patient had associated Candida
endocarditis (20%). The four patients with hepatitis C
were not being treated with antiviral therapy at the time
of presentation. Two patients had intravenous lines in
situ at the time of presentation (40%). All five patients
had no previous ophthalmic history, and all had best-
corrected visual acuities of better than 20/32 in both
eyes before presentation for endophthalmitis.
Presentation and diagnosis
In terms of referral pathway, three patients presented to
the hospital ophthalmology outpatient department with
a mean time from onset of symptoms to ophthalmologic
review of 6.3 days. Two patients were current hospital
inpatients, and the mean time from onset of symptoms
to ophthalmologic review in these patients was 1 day.
The right eye was affected in three cases and the left eye
in one case, and there was one case of bilateral endoph-
thalmitis. Visual acuity was 20/200 or worse in the affected
eye in all patients at presentation (Table 1). The major
presenting symptom in all cases was decreased visual acu-
ity. On examination, all patients had severe anterior cham-
ber inflammation and severe vitritis. No patient presented
with hypopyon. Two patients had evidence of vitreous
snowballs.
Diagnostic testing and microbiology
Systemically, all patients had blood cultures, HIV serology,
and echocardiography on presentation. A total of 19 blood
cultures were collected from the five patients (mean 3.8
per patient, range 1–8). Only 4 of these 19 cultures were
positive for C. dubliniensis (22%), and all 4 of these were
collected from the patient with bilateral endophthalmitis.
All patients were HIV negative on serology at the time ofpresentation. Echocardiography showed associated endo-
carditis in one patient.
In terms of ophthalmic investigations, between the six
eyes, five vitreous taps were performed with three sam-
ples (60%) producing positive C. dubliniensis cultures.
No anterior chamber taps were performed. Seven vitrec-
tomy samples were taken from the six eyes with three
intraoperative vitreous samples (43%) producing positive
C. dubliniensis cultures. The mean length of time for
notification of a positive vitreous C. dubliniensis culture
was 5.4 days (range 3–10 days). In terms of antifungal
sensitivities, all six isolates were sensitive to fluconazole,
5-flucytosine, and voriconazole; however, only three iso-
lates were sensitive to amphotericin B.
Treatment
In terms of initial treatment, five eyes (83%) from four
patients were treated with vitreous tap, intravitreal injec-
tion of an antifungal agent, and systemic antifungal ther-
apy on the day of presentation. One eye from one patient
was initially treated with urgent vitrectomy, intravitreal in-
jection of an antifungal agent, and systemic antifungal
therapy on the day of presentation (17%).
Systemically, the empirical antifungal agent adminis-
tered was fluconazole in two patients (40%), voriconazole
in two patients (40%), and amphotericin B in one patient.
Once positive C. dubliniensis culture was obtained, three
patients were treated with systemic fluconazole (60%) and
two patients were treated with systemic voriconazole
(40%). For the patients treated with fluconazole, the mean
duration of treatment was 40 days (range 36–42 days). For
the patients treated with voriconazole, the mean duration
of treatment of 40.5 days (range 35–46 days).
In terms of ophthalmic treatment, all six infected eyes
received intravitreal antifungal injections. A total of 33
intravitreal injections were given - 22 voriconazole and
11 amphotericin B. The mean number of intravitreal in-
jections per eye was 5.5 (range 3–10), and the mean
interval between intravitreal injections was 4.2 days.
All eyes underwent vitrectomy at least once for clear-
ance of infection. The mean time from onset of symptoms
to the first vitrectomy was 20.5 days (range 1–43 days).
Only one vitrectomy was performed urgently on the day
of presentation for diagnosis and for early clearance of
infection due to extensive vitreous snowballs. In total,
eight vitrectomies were performed on the six eyes - two
eyes required two vitrectomies due to subsequent retinal
detachments which required repair.
Visual outcomes and mortality
There was no associated mortality in our series, and no
infected eye required enucleation or evisceration. No
patient developed any secondary fungal infection during
follow-up or experienced any systemic complications.
Table 1 Endogenous C. dubliniensis endophthalmitis cases




Antifungal sensitivity Antifungal treatment and surgery Final visual
acuity
Sedeek, 2008 [4] M, 38 Nil Right eye Not
reported





Urgent lensectomy/vitrectomy, IVI vancomycin/ceftazidime.
IVI/topical amphotericin B, PO voriconazole (no duration)
Not reported
Pelegrin, 2010 [5] M, 41 IVDU, HIV+, hepatitis





VA RE - 20/200,
LE - 20/400
Azoles Vitrectomy, IVI amphotericin B. Systemic voriconazole then
PO fluconazole for 2 months







VA LE - 20/400 Fluconazole and all other
agents tested
Toxoplasma treatment. IV fluconazole. Vitrectomy/IVI
amphotericin B. PO fluconazole for 6 weeks
VA LE - 20/80
Present case 1 M, 50 IVDU, hepatitis C Right eye Walk-in to
eye
outpatients





Empirical IVI amphotericin B. Vitrectomy. 2× IVI
amphotericin B. PO voriconazole for 46 days
VA RE - 20/30,
LE - 20/16
Present case 2 M, 28 IVDU Right eye Walk-in to
eye
outpatients




Urgent vitrectomy/IVI voriconazole. Empirical systemic
voriconazole. 3× IVI amphotericin B. Vitrectomy/buckle/gas.
PO fluconazole for 42 days
VA RE - 20/60,
LE - 20/20








Empirical fluconazole, IVI amphotericin B. 2× IVI
amphotericin B. Vitrectomy. PO voriconazole for 35 days.
Vitrectomy/buckle/gas
VA RE - HM,
LE - 20/20









Empirical fluconazole. Right vitrectomy. 10× IVI
voriconazole RE. 4× IVI voriconazole LE. Left vitrectomy.
PO fluconazole for 42 days
VA RE - 20/60,
LE - 20/60
Present case 5 F, 21 IVDU, hepatitis C Left eye Walk-in to
eye
outpatients





Empirical voriconazole, IVI amphotericin B. 8× IVI
voriconazole. Vitrectomy. PO fluconazole for 36 days
VA RE - 20/16,
LE - 20/30
Abbreviations: CF counting fingers, F female, HM hand movements, IVDU intravenous drug use, IVI intravitreal injection, LE left eye, M male, PICC peripherally inserted central catheter, PO per oral, RE right eye,
































Number of patients 5 3 8
Number of eyes involved 6 3 9
Diagnosis and microbiology
Vitreous taps 5 1 6
Positive fungal vitreous
taps
3 (60%) 1 (100%) 4 (67%)
Vitrectomy specimens 7 3 10
Positive fungal vitrectomy
specimens




3 (50%) 2 (66%) 5 (56%)
Intravitreal voriconazole
(number of eyes)
4 (66%) 0 4 (44%)





Empirical fluconazole 2 (40%) 1 (33%) 3 (38%)
Empirical voriconazole 2 (40%) 1 (33%) 3 (38%)
Definitive fluconazole
therapy
3 (60%) 2 (66%) 5 (56%)
Definitive voriconazole
therapy









acuity better than 20/80
5 (83%) 2 (100%) 7 (87%)a
Final best-corrected visual
acuity worse than 20/200
1 (17%) 0 1 (13%)a
Retinal detachment 2 (33%) 0 2 (22%)
Enucleation/evisceration 0 0 0
Mortality 0 0 0
aDetails of final visual acuity have been described only in eight cases.
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best-corrected visual acuity of 20/60 or better and one
eye had a poor final visual acuity of hand movements
only. No eyes developed associated cataract or glaucoma.
Two eyes did develop retinal detachment over the
course of the endophthalmitis which required surgical
repair. Both detachments were caused by single superior
retinal tears. The maculae were still attached on the day
of diagnosis and repair in both cases. The first of thesetwo patients had initially undergone urgent vitrectomy
on the day of presentation, and subsequent retinal de-
tachment occurred 10 days later. This patient eventually
had final best-corrected visual acuity of 20/60. The second
patient had an initial vitrectomy 12 days after presentation
and developed retinal detachment 2 days later. This
patient eventually had final best-corrected visual acuity
of hand movements only.
Discussion
It is well documented that Candida species are among
the most common known fungal pathogens. They can
cause a wide range of diseases in humans from superfi-
cial mucosal infections to life-threatening disseminated
diseases. By far, the most prevalent isolated strain is
C. albicans which has been implicated in up to 65% of
cases of candidemia [7]. Although C. albicans has been
shown to have low virulence in healthy individuals,
candidemia is associated with relatively high rates of
morbidity and mortality [8]. Among patients with diag-
nosed candidemia, reported rates of associated en-
dogenous endophthalmitis range from less than 3% to
44% and mortality rates in these patients have been re-
ported as high as 77% [9]. Candida species reported to
cause endophthalmitis include C. albicans, C. tropicalis, C.
parapsilosis, C. glabrata, C. guilliermondii, C. krusei, and
most recently C. dubliniensis.
C. dubliniensis was first described in 1995 in Dublin,
Ireland, among HIV-infected patients with oral candidiasis
[2]. It has been found to be only a minor component of
the oral flora of humans, and although it primarily causes
oral candidiasis in HIV-infected and immunocomprom-
ised patients, rare reports of invasive systemic infections
in both HIV-positive and HIV-negative patients have been
documented [10-12]. This is consistent with large epi-
demiological studies which report that candidemia caused
by C. dubliniensis has only rarely been identified and
represents around 2% of yeast-positive blood cultures
[7]. The rare isolation of C. dubliniensis has also likely
been due to its close phenotypic similarity to C. albicans
resulting in often misidentification in laboratory settings.
In fact, retrospective studies of Candida isolates in fun-
gal stock collections going back to the 1970s have since
found many cases of C. dubliniensis that were mis-
takenly identified as C. albicans [13-15]. This suggests
that C. dubliniensis has probably been present in the
community for a much longer period than its recent
discovery indicates and could also suggest that many cases
of C. dubliniensis endophthalmitis have been wrongly
attributed to C. albicans in previous published literature.
Thus, due to its rare nature, only recent identification,
and probable previous misidentification, C. dubliniensis
has only rarely been reported as the causative organism
in endophthalmitis. Although the sample size of our series
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endophthalmitis represent the largest single case series
published to date with only three other previously re-
ported cases to our knowledge in the literature (Tables 1
and 2) [4-6]. The significance of these now eight total
cases is important because recent studies have shown that
C. dubliniensis is less pathogenic than C. albicans and this
may have implications for the diagnosis and treatment of
endophthalmitis caused by these separate organisms.
Comparing the five cases in our series with the three
previous cases (Tables 1 and 2), it is clear that risk factors
for endogenous C. dubliniensis endophthalmitis include
male gender, intravenous drug use, hepatitis, liver disease,
placement of an intravenous catheter, and endocarditis. It
is also important to note that only one previous patient
has been HIV positive [5]. In terms of presentation, often
these cases present as isolated endophthalmitis infec-
tions without any other systemic evidence of dissemi-
nated disease.
Diagnosis in C. dubliniensis endophthalmitis can be
difficult because the organism has high false-negative
rates on fungal cultures of both vitreous samples and
blood cultures. However, the sensitivities of these investi-
gations in our series were improved compared to previous
C. albicans endophthalmitis series [16]. Microbiologically,
although fluconazole-resistant isolates of C. dubliniensis
have been described due to overexpression of genes en-
coding multidrug transporter proteins [17], all isolates
from the reported cases of C. dubliniensis endophthalmitis
have been susceptible not only to fluconazole but most
other conventional antifungal agents (Table 1).
In terms of treatment and outcomes, vitrectomy, re-
peated intravitreal injection, and systemic antifungal
therapy appear to be efficacious in C. dubliniensis en-
dophthalmitis with 87% of infected eyes recovering
vision of 20/80 or better. Only retinal detachment ap-
pears to be associated with poorer visual outcomes,
while surprisingly, early vitrectomy, increased number
of intravitreal injections, and delayed presentation all
appear to not influence visual outcomes.
Most interestingly, the visual outcomes for endogenous
C. dubliniensis endophthalmitis appear to be slightly bet-
ter when compared to a recent study into visual outcomes
in endogenous C. albicans endophthalmitis cases [16].
In this study, 33% of patients with C. albicans endoph-
thalmitis had a final visual acuity of 20/200 or worse
and 52% of patients had a final visual acuity of 20/40 or
worse [16]. These differences in visual outcomes be-
tween C. dubliniensis endophthalmitis and the more
common C. albicans endophthalmitis support the hy-
pothesis suggested by Moran et al. that C. dubliniensis
is less pathogenic than C. albicans due to the decreased
ability of C. dubliniensis to produce hyphae and its
intolerance to environmental stressors [18]. This isfurther supported by the reduced associated systemic
mortality in C. dubliniensis endophthalmitis.Conclusions
Overall, C. dubliniensis is a rare cause of both candide-
mia and endogenous endophthalmitis and can present
in both HIV-positive and HIV-negative patients. Based
on the albeit limited number of reported endophthalmitis
cases caused by this organism, we recommend treatment
with intravitreal voriconazole to avoid possible amphoteri-
cin B resistance, followed by vitrectomy for clearance of
infection and a 6-week course of systemic fluconazole
therapy. Although this organism can be resistant to flu-
conazole, there is no documented case of C. dubliniensis
endophthalmitis where the isolate has shown this resist-
ance. In addition, although this treatment regime may be
complicated by retinal detachment, overall it appears to be
associated with improved visual outcomes compared
to cases caused by C. albicans and does not lead to any
associated systemic morbidity or mortality.
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